Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Shaanxi, Xi׳an 710032, PR China.
Health Department of General Logistics Department, CPLA, Beijing 010842, PR China.
J Ethnopharmacol. 2014 Sep 11;155(2):1053-60. doi: 10.1016/j.jep.2014.05.061. Epub 2014 Jun 21.
Combination of Radix Astragali (Huangqi) and Carthamus tinctorius L. (Honghua) has been extensively used as traditional herb medicine in China for the treatment of stroke and myocardial ischemia diseases with Qi deficiency and blood stasis (QDBS) syndrome.
To investigate the effect of Huangqi-Honghua combination (HH) and its main components astragaloside IV (AS-IV) and Hydroxysafflor yellow A (HSYA) on cerebral ischemia-reperfusion (IR) with QDBS in rat model.
Male rats were randomly divided into the following six groups: sham group, QDBS+I/R model group and treatment group including AS-IV, HSYA, AS-IV+HSYA and HH. The whole blood viscosity (WBV), plasma viscosity (PV), neurological examination, infarct volume, histopathology changes and some oxidative stress markers were assessed after 24h of reperfusion.
HH and its main components AS-IV+HSYA could significantly decrease WBV, PV, and also significantly ameliorate neurological examination and infarct volume after 24h of reperfusion. They also significantly increased expression of Nuclear factor erythroid 2-related factor 2 (Nrf2), activities of antioxidants, such as superoxide dismutase (SOD), catalase and glutathione peroxidase (GSH-Px), led to decrease levels of malondialdehyde (MDA) and reactive oxygen species (ROS).
AS-IV and HSYA are responsible for the main curative effects of HH. The study may provide scientific information to further understanding the mechanism(s) of HH and its main components in removing blood stasis and ameliorating cerebral infarction. Additionally, AS-IV and HSYA appear to have synergistic effects on neuroprotection.
药效学相关性:黄芪和红花的组合在中国被广泛用作治疗气虚血瘀(QDBS)综合征中风和心肌缺血疾病的传统草药。
目的:研究黄芪-红花(HH)及其主要成分黄芪甲苷(AS-IV)和羟基红花黄色素 A(HSYA)对 QDBS 大鼠脑缺血再灌注(IR)的影响。
材料和方法:雄性大鼠随机分为以下六组:假手术组、QDBS+I/R 模型组和 AS-IV、HSYA、AS-IV+HSYA 和 HH 治疗组。在再灌注 24 小时后评估全血黏度(WBV)、血浆黏度(PV)、神经学检查、梗死体积、组织病理学变化和一些氧化应激标志物。
结果:HH 及其主要成分 AS-IV+HSYA 可显著降低 WBV 和 PV,显著改善再灌注 24 小时后的神经学检查和梗死体积。它们还显著增加核因子红细胞 2 相关因子 2(Nrf2)的表达,提高抗氧化剂如超氧化物歧化酶(SOD)、过氧化氢酶和谷胱甘肽过氧化物酶(GSH-Px)的活性,降低丙二醛(MDA)和活性氧(ROS)的水平。
结论:AS-IV 和 HSYA 是 HH 的主要疗效成分。该研究可能为进一步了解 HH 及其主要成分祛瘀和改善脑梗死的机制提供科学信息。此外,AS-IV 和 HSYA 对神经保护似乎具有协同作用。